Abstract
Adenocarcinoma of the pancreas remains among the most lethal cancers in the United States. For most of the past four decades, little has changed in the treatment and poor survival associated with this tumor [1]. Surgery is still the only treatment associated with cure, though most patients have unresectable disease at diagnosis. Even in favorable, resectable disease, median survival is only 15-24 months [2, 3], with 15-20% long-term survival. Aggressive chemo-radiotherapy trials have demonstrated only marginal improvements in overall survival, rarely with long-term survival.
| Original language | English (US) |
|---|---|
| Title of host publication | Treating Tumors that Move with Respiration |
| Publisher | Springer Berlin Heidelberg |
| Pages | 241-246 |
| Number of pages | 6 |
| ISBN (Print) | 9783540698852 |
| DOIs | |
| State | Published - 2007 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas : Initial experience at Sinai Hospital of Baltimore. / Hoffelt, Christopher; Didolkar, Mukund.
Treating Tumors that Move with Respiration. Springer Berlin Heidelberg, 2007. p. 241-246.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas
T2 - Initial experience at Sinai Hospital of Baltimore
AU - Hoffelt, Christopher
AU - Didolkar, Mukund
PY - 2007
Y1 - 2007
N2 - Adenocarcinoma of the pancreas remains among the most lethal cancers in the United States. For most of the past four decades, little has changed in the treatment and poor survival associated with this tumor [1]. Surgery is still the only treatment associated with cure, though most patients have unresectable disease at diagnosis. Even in favorable, resectable disease, median survival is only 15-24 months [2, 3], with 15-20% long-term survival. Aggressive chemo-radiotherapy trials have demonstrated only marginal improvements in overall survival, rarely with long-term survival.
AB - Adenocarcinoma of the pancreas remains among the most lethal cancers in the United States. For most of the past four decades, little has changed in the treatment and poor survival associated with this tumor [1]. Surgery is still the only treatment associated with cure, though most patients have unresectable disease at diagnosis. Even in favorable, resectable disease, median survival is only 15-24 months [2, 3], with 15-20% long-term survival. Aggressive chemo-radiotherapy trials have demonstrated only marginal improvements in overall survival, rarely with long-term survival.
UR - http://www.scopus.com/inward/record.url?scp=84891403439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891403439&partnerID=8YFLogxK
U2 - 10.1007/978-3-540-69886-9_24
DO - 10.1007/978-3-540-69886-9_24
M3 - Chapter
AN - SCOPUS:84891403439
SN - 9783540698852
SP - 241
EP - 246
BT - Treating Tumors that Move with Respiration
PB - Springer Berlin Heidelberg
ER -